Browse our anti-BCL9 (BCL9) Antibodies

On are 41 B-Cell CLL/lymphoma 9 (BCL9) Antibodies from 10 different suppliers available. Additionally we are shipping BCL9 Proteins (6) and BCL9 Kits (5) and many more products for this protein. A total of 52 BCL9 products are currently listed.
2610202E01Rik, 8030475K17Rik, A330041G23Rik, BCL9, Gm130, legless, LGS, MGC83888, xbcl9
list all antibodies Gene Name GeneID UniProt
BCL9 77578 Q9D219
BCL9 607 O00512
BCL9 310704  

Most Popular Reactivities for anti-BCL9 (BCL9) Antibodies

anti-Mouse (Murine) BCL9 Antibodies:

anti-Human BCL9 Antibodies:

anti-Rat (Rattus) BCL9 Antibodies:

All available anti-BCL9 Antibodies

Go to our pre-filtered search.

More Antibodies against BCL9 Interaction Partners

Xenopus laevis B-Cell CLL/lymphoma 9 (BCL9) interaction partners

  1. Both XBcl9 and XPygo2 are required to induce supernumerary axis and dorsal gene activation in Xenopus embryos.

Mouse (Murine) B-Cell CLL/lymphoma 9 (BCL9) interaction partners

  1. ARX positively regulates Wnt (show WNT2 Antibodies)/ beta-catenin (show CTNNB1 Antibodies) signaling and the C-terminal domain of ARX interacts with the armadillo (show PKP1 Antibodies) repeats in beta-catenin (show CTNNB1 Antibodies) to promote Wnt (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies) signaling. In addition, we found BCL9 and P300 (show NOTCH1 Antibodies) also interact with ARX to modulate Wnt (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies) signaling.

  2. Study demonstrates that the Golgi resident protein GM130 (show GOLGA2 Antibodies) activates the spindle assembly factor TPX2 (show DAZL Antibodies) to nucleate microtubules around the Golgi and further captures them to couple mitotic membranes to the spindle.

  3. Pax6 (show PAX6 Antibodies), the master regulator of eye development, directly activates Bcl9/9l transcription.

  4. These results suggest a critical role of BCL9/9-2 in the Wnt (show WNT2 Antibodies)-mediated regulation of adult, as opposed to embryonic, myogenic progenitors.

Human B-Cell CLL/lymphoma 9 (BCL9) interaction partners

  1. MEF2D (show MEF2D Antibodies)-BCL9-positive patients had B-cell precursor immunophenotype and were characterized as being older in age, being resistant to chemotherapy, having very early relapse, and having leukemic blasts that mimic morphologically mature B-cell leukemia with markedly high expression of HDAC9 (show HDAC9 Antibodies).

  2. it was demonstrated that miR218 modulated a novel molecular target and the present study provided novel insights into potential mechanisms of RCC (show XRCC1 Antibodies) oncogenesis.

  3. findings indicate that BCL9 most likely does not harbor a common genetic variant that can increase the risk for schizophrenia in the Japanese population

  4. BCL9/9L-beta-catenin (show CTNNB1 Antibodies) Signaling is Associated With Poor Outcome in Colorectal Cancer

  5. BCL9 is a molecular driver of DCIS invasive progression.

  6. PCDH10 (show PCDH10 Antibodies) antagonized MM cell proliferation via the downregulation of Wnt (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies)/BCL-9 signaling, whereas PCDH10 (show PCDH10 Antibodies) repressed the expression of AKT (show AKT1 Antibodies) to promote the expression of GSK3beta (show GSK3b Antibodies) and then to restrain the activation of beta-catenin (show CTNNB1 Antibodies)

  7. By beta-catenin's association with LEF1 (show LEF1 Antibodies) and BCL9-2/B9L (show BCL9L Antibodies).

  8. MiR (show MLXIP Antibodies)-30-5p downregulation occurs as a result of interaction between multiple myeloma cells and bone marrow stromal cells, which in turn enhances expression of BCL9.

  9. we detected five SNPs in the first two genes/loci - BCL9 and C9orf5 - strongly associated with negative symptoms of schizophrenia

  10. Inhibition of the BCL9-beta-catenin (show CTNNB1 Antibodies) interaction and selectively suppresses oncogenic Wnt (show WNT2 Antibodies) transcription.

BCL9 Antigen Profile

Antigen Summary

BCL9 is associated with B-cell acute lymphoblastic leukemia. It may be a target of translocation in B-cell malignancies with abnormalities of 1q21. Its function is unknown. The overexpression of BCL9 may be of pathogenic significance in B-cell malignancies.

Alternative names and synonyms associated with BCL9

  • B-cell CLL/lymphoma 9 (bcl9) antibody
  • B-cell CLL/lymphoma 9 (BCL9) antibody
  • B cell CLL/lymphoma 9 (Bcl9) antibody
  • B-cell CLL/lymphoma 9 (Bcl9) antibody
  • 2610202E01Rik antibody
  • 8030475K17Rik antibody
  • A330041G23Rik antibody
  • BCL9 antibody
  • Gm130 antibody
  • legless antibody
  • LGS antibody
  • MGC83888 antibody
  • xbcl9 antibody

Protein level used designations for BCL9

B-cell CLL/lymphoma 9 , B-cell lymphoma 9 , B-cell CLL/lymphoma 9 protein-like , b-cell CLL/lymphoma 9 protein-like , B-cell CLL/lymphoma 9 protein , B-cell lymphoma 9 protein , bcl-9 , nuclear co-factor of beta-catenin signalling , protein legless homolog

431941 Xenopus laevis
457248 Pan troglodytes
100405208 Callithrix jacchus
100440022 Pongo abelii
100481271 Ailuropoda melanoleuca
77578 Mus musculus
607 Homo sapiens
100155378 Sus scrofa
418456 Gallus gallus
483154 Canis lupus familiaris
788729 Bos taurus
310704 Rattus norvegicus
Selected quality suppliers for anti-BCL9 (BCL9) Antibodies
Did you look for something else?